These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 1762088)

  • 41. Stereoselective metabolism and pharmacokinetics of racemic methylphenobarbital in humans.
    Lim WH; Hooper WD
    Drug Metab Dispos; 1989; 17(2):212-7. PubMed ID: 2565213
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Stereoselective pharmacokinetic analysis of tramadol and its main phase I metabolites in healthy subjects after intravenous and oral administration of racemic tramadol.
    García Quetglas E; Azanza JR; Cardenas E; Sádaba B; Campanero MA
    Biopharm Drug Dispos; 2007 Jan; 28(1):19-33. PubMed ID: 17061296
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Stereoselective verapamil disposition and dynamics in aging during racemic verapamil administration.
    Abernethy DR; Wainer IW; Longstreth JA; Andrawis NS
    J Pharmacol Exp Ther; 1993 Aug; 266(2):904-11. PubMed ID: 8355215
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Stereoselective renal tubular secretion of a new uricosuric diuretic, 6,7-dichloro-5-(N,N-dimethylsulfamoyl)-2,3-dihydro-2-benzofurancarboxyl ic acid (S-8666), in cynomolgus monkeys.
    Nakano M; Kawahara S
    Drug Metab Dispos; 1992; 20(2):179-85. PubMed ID: 1352207
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Route-dependent stereoselective pharmacokinetics of tramadol and its active O-demethylated metabolite in rats.
    Parasrampuria R; Vuppugalla R; Elliott K; Mehvar R
    Chirality; 2007 Mar; 19(3):190-6. PubMed ID: 17192836
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Stereoselective pharmacokinetics and pharmacodynamics of disopyramide and its metabolite in rabbits.
    Horikawa M; Yasumuro M; Kanno M; Hanada K; Hashiguchi M; Ogata H
    J Pharm Pharmacol; 2001 Dec; 53(12):1621-8. PubMed ID: 11804392
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Relationship between alpha 1-acid glycoprotein and distribution of disopyramide and mono-N-dealkyldisopyramide in whole blood.
    Bredesen JE; Kierulf P
    Br J Clin Pharmacol; 1986 Sep; 22(3):281-6. PubMed ID: 3768240
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Relationship between alpha 1-acid glycoprotein and plasma binding of disopyramide and mono-N-dealkyldisopyramide.
    Bredesen JE; Kierulf P
    Br J Clin Pharmacol; 1984 Nov; 18(5):779-84. PubMed ID: 6508986
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Enantioselective analysis of disopyramide and mono-N-dealkyldisopyramide in plasma and urine by high-performance liquid chromatography on an amylose-derived chiral stationary phase.
    Bortocan R; Lanchote VL; Cesarino EJ; Bonato PS
    J Chromatogr B Biomed Sci Appl; 2000 Jul; 744(2):299-306. PubMed ID: 10993518
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effect of concentration-dependent binding to plasma proteins on the pharmacokinetics and pharmacodynamics of disopyramide.
    Giacomini KM; Blaschke TF
    Clin Pharmacokinet; 1984 Jan; 9 Suppl 1():42-8. PubMed ID: 6705426
    [TBL] [Abstract][Full Text] [Related]  

  • 51. In vivo interaction of the enantiomers of disopyramide in human subjects.
    Giacomini KM; Nelson WL; Pershe RA; Valdivieso L; Turner-Tamiyasu K; Blaschke TF
    J Pharmacokinet Biopharm; 1986 Aug; 14(4):335-56. PubMed ID: 3772736
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Antiarrhythmic activity and unbound concentrations of disopyramide enantiomers in patients.
    Lima JJ; Wenzke SC; Boudoulas H; Schaal SF
    Ther Drug Monit; 1990 Jan; 12(1):23-8. PubMed ID: 2305417
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effects of serum concentrations of disopyramide and its metabolite mono-N-dealkyldisopyramide on the anticholinergic side effects associated with disopyramide.
    Tsuchishita Y; Fukumoto K; Kusumoto M; Ueno K
    Biol Pharm Bull; 2008 Jul; 31(7):1368-70. PubMed ID: 18591776
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Stereoselective differences in propranolol disposition in female Sprague-Dawley and Dark Agouti rats.
    Guttendorf RJ; Kostenbauder HB; Wedlund PJ
    Drug Metab Dispos; 1991; 19(1):251-6. PubMed ID: 1673410
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Enantioselective tissue distribution of the basic drugs disopyramide, flecainide and verapamil in rats: role of plasma protein and tissue phosphatidylserine binding.
    Hanada K; Akimoto S; Mitsui K; Mihara K; Ogata H
    Pharm Res; 1998 Aug; 15(8):1250-6. PubMed ID: 9706057
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Stereoselective pharmacokinetics of disopyramide and interaction with cimetidine.
    Bonde J; Pedersen LE; Nygaard E; Ramsing T; Angelo HR; Kampmann JP
    Br J Clin Pharmacol; 1991 Jun; 31(6):708-10. PubMed ID: 1867965
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Bioavailability of disopyramide in normal volunteers using unbound concentration.
    Braun J; Sörgel F; Gluth WP; Oie S
    Eur J Clin Pharmacol; 1987; 32(6):625-9. PubMed ID: 3653232
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The effect of saturable binding to plasma proteins on the pharmacokinetic properties of disopyramide.
    Giacomini KM; Swezey SE; Turner-Tamiyasu K; Blaschke TF
    J Pharmacokinet Biopharm; 1982 Feb; 10(1):1-14. PubMed ID: 7069575
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Clinical pharmacokinetics of disopyramide.
    Siddoway LA; Woosley RL
    Clin Pharmacokinet; 1986; 11(3):214-22. PubMed ID: 3524956
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Nomogram for estimating plasma unbound disopyramide concentrations in patients with varying plasma alpha 1-acid glycoprotein concentrations.
    Echizen H; Ishikawa S; Koike K; Ishizaki T
    Ther Drug Monit; 1995 Apr; 17(2):145-52. PubMed ID: 7624903
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.